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Background~Aims: Cysteinyl-containing leukotrienes 
seem to exert a cholestatic effect. However, leuko- 
triene inhibitors were found to reduce bile salt efflux in 
isolated rat hepatocytes, suggesting a role for leuko- 
trienes in bile flow formation. Methods: In the isolated 
rat liver, the effects of two different concentrations of 
leukotriene C4 on bile flow and bile salt excretion are 
analyzed, as well as the possible effect of taurocholate 
on the hepatic production of cysteinyl-containing leuko- 
trienes. Results: Leukotriene C4 (0.25 fmol) increased 
bile salt excretion (+22.2%; P < 0.05), whereas a 
much higher dose (0.25 x 10 e fmol) showed the known 
cholestatic effect, reducing bile salt excretion ( -25.9%; 
P < 0.01). These dose-dependent biphasic effects 
were specific because they could be prevented by the 
simultaneous administration of cysteinyl-containing 
leukotriene antagonists. On the other hand, taurocho- 
late administration induced a dose-dependent increase 
in biliary excretion of cysteinyl-containing leukotrienes. 
Furthermore, taurocholate increased messenger RNA 
levels of 5-1ipoxygenase, a key enzyme in leukotriene 
biosynthesis. Taurocholate increase of hepatocyte in- 
tracellular calcium was not significant, suggesting that 
taurocholate effects are not mediated by stimulation 
of calcium metabolism. Conclusions: These results 
constitute evidence for the existence of a positive feed- 
back mechanism by which bile salts stimulate the syn- 
thesis of leukotrienes that, in turn, stimulate bile salt 
excretion. 
B ile salts are the main promoters of bile flow, and considerable efforts have been made to understand 
the mechanisms of their uptake, hepatocellular transport, 
and biliary excretion. 1-3 However, very little is known 
about the possible role of arachidonic acid derivatives 
and, in particular, of leukotrienes (LTs) in the secretion 
of bile salts by the liver. 
5-Lipoxygenase is a key enzyme in the cascade leading 
to LTs. It is responsible for the formation of 5-hydroper- 
oxyeicosatetraenoic acid (5-HPETE) from arachidonic 
acid, and its further dehydration into LTA4, a pivotal 
intermediate in leukotriene biosynthesis. 4'5 Hydrolysis of 
LTA4 may lead to either LTB4 if catalyzed by LTA4 
hydrolase or 5,6-DHETE if catalyzed by cytosolic epox- 
ide hydrolase. The enzymatic addition of glutathione to 
LTA4 leads to LTC4, which may be subsequently trans- 
formed into LTD4 and LTE4. LTC~, LTD4, and LTE4 
are referred to as cysteinyl-containing LTs and constitute 
the slow-reacting substance of anaphylaxis. 
Cysteinyl-containing LTs have been found to be the 
main metabolites of LTA4 in rat liver. 6 Although they 
have been implicated in the stimulation of secretory pro- 
cesses in several tissues and cells/'8 all of the actions 
ascribed to these LTs in the liver have been related to 
the production of tissue injury 9 and cholestasis.10 On the 
other hand, previous tudies in our laboratory have shown 
that several inhibitors of 5-1ipoxygenase impaired bile 
salt efflux in isolated rat hepatocytes. 11 Also, the cys- 
teinyl-containing LT antagonist FPL 55712 has been 
reported to reduce the bile flow in anesthetized rats. 12 
All of these data taken together strongly suggest hat 
LTs may have a role in the excretion of bile salts and 
therefore in the genesis of bile flow. In this study, we 
have analyzed the effect of two different doses of LTC4 
on biliary bile salt excretion in the isolated and perfused 
rat liver. We have also studied the possible effect of 
taurocholate, a main physiological bile salt in the rat, on 
LTC4 biosynthesis in the liver. 
Mater ia l s  and  Methods  
Taurocholic acid (sodium salt), bovine serum albumin, 
4-hydroxy-2,2,6,6-tetramethylpiperidine-l-oxyi (HTMP), and 
L-phenylephrine were obtained from Sigma Chemical Co. (St. 
Louis, MO). FPL 55712 was a gift from Fisons Pharmaceutical 
Ltd. (Loughborough, England), and REV 5901 was purchased 
from Cascade Biochem (Reading, England); Leibovitz L-15 
Abbreviations used in this paper: AM, acetoxymethyl ester; [Ca2+] i  , 
intracellular free calcium concentration; 5-HPETE, 5-hydroperoxyeico- 
satetraenoic acid; HTMP, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1- 
oxyl; LDH, lactate dehydrogenase; LT, leukotriene; RT-PCR, reverse- 
transcription polymerase chain reaction. 
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medium from Whittaker (Walkersville, MD); laminin from 
ICN Biomedicals (Costa Mesa, CA); Fura-2/acetoxymethyl es- 
ter (AM) from Molecular Probes (Eugene, OR); [3H]LTC4, and 
[32p]deoxycytidine triphosphate were from Amersham (Little 
Chalfont, England). Synthetic oligonucleotides were purchased 
from Scandinavian Gene Synthesis AB (K6ping, Sweden); re- 
verse transcriptase from GIBCO BRL (Gaithersburg, MD); and 
Taq DNA polymerase from Promega (Madison, WI). All other 
chemicals were of the highest purity commercially available. 
Isolated Rat Liver Perfusion 
Isolated livers from male Wistar rats (230-290 g body 
wt) were used in a recirculating retrograde perfusion system. 
Liver isolation was as described by Meijer et al. 13 with minor 
modifications. Briefly, the bile duct was first cannulated with 
a polyethylene tubing PE-50, followed by cannulation of the 
vena porta with a catheter Abbocath 16-G. After the catheter 
was tied in place, the liver was immediately perfused in situ 
(~20 mL/min of oxygenated and heparinized Krebs-Ringer 
bicarbonate buffer at 37°C), and the inferior vena cava was cut 
simultaneously to avoid an increase in the perfusion pressure. 
The diaphragm was then opened, the thoracic vena cava was 
cannulated with a polyethylene cannula (1.5-mm inner diame- 
ter), and a ligature previously set around the vena cava, proxi- 
mal to the insertion of the right renal vein, was closed. Once 
the adhesions of the liver and the vena cava were carefully cut, 
the liver was transferred to an acrylic platform and placed 
into a chamber for perfusion in a recirculating system with 
approximately 30 mL/min of Krebs-Ringer bicarbonate buffer 
supplemented with 5.5 mmol/L glucose and 3% bovine serum 
albumin at 37°C. Oxygenation was ensured by passing the 
medium through a glass gas exchanger continuously flushed 
with 95% 02/5% CO2. 
The protocol of treatment of the livers was as follows. After 
a 20-minute stabilization period and a further 20-minute basal 
period, a bolus of 500 [.tL of saline buffer containing the sub- 
stances to be tested was injected, and the experiment was 
continued for another 20 minutes (stimulation period). We 
studied the effect of the following substances: 3 or 12 [.tmol 
of taurocholate, 0.25 fmol or a 106-fold higher amount (i.e., 
0.25 X 106 fmol) ofLTC4, and the same doses of LTC4 together 
with cysteinyl-containing LT antagonists (either FPL 55712 
or REV 5901, 6.25 × 106 fmol for both). Bile effluents were 
collected at the end of each 20-minute period. 
Some livers were preloaded with tritiated LTC4, and the 
effect of taurocholate administration on the biliary excretion 
of LTC4 was tested in these livers. Approximately 100,000 
dpm of [3H]LTC4 (dissolved in 500 /.tL of saline buffer as 
vehicle) was injected after a basal period of 20 minutes. Thirty 
minutes later, a bolus with saline vehicle containing 3 btmol 
of taurocholate was administered, and the biliary excretion of 
cysteinyl-containing LTs was monitored uring a further 45- 
minute period. In these experiments, bile effluents were col- 
lected every 15 minutes. 
In the experiments in which the effect of LTC4 on bile flow 
and bile salt excretion was tested, a continuous infusion of 
taurocholate (15 btmol/h) was maintained to counteract the 
loss of bile salts due to the interruption of the enterohepatic 
circulation. 
In addition to the experiments with bolus injections, astudy 
with continuous infusion of taurocholate (120 or 15 [.tmol/ 
h) was performed, initiated after the stabilization period and 
continued for 90 minutes. Bile effluents were collected every 
15 minutes. Bile flow was calculated by weighing the collected 
aliquots. 
The viability of the liver during the experiments was as- 
sessed by measuring the levels of aspartate aminotransferase 
(AST), lactate dehydrogenase (LDH), and potassium in the 
hepatic effluent and by verifying the bile production and the 
macroscopic aspect of the liver.13 Liver metabolism was assessed 
by measuring the hepatic release of glucose, lactate, and py- 
ruvate. No significant differences in the values of AST, LDH, 
potassium, and glucose were found between groups except after 
the administration of the highest doses of LTC4 (0.25 X 106 
fmol), which altered significantly some of these parameters ( ee 
Results). 
Bile Salt and LT Analysis 
Total bile acids were determined in bile using a com- 
mercially available kit from Merck (Darmstadt, Germany). To 
determine the excretion of LTC4 and LTD4 (the main cysteinyl- 
containing LTs in bile from isolated rat liver14), 25 btL of bile 
was collected in 200 ~tL of methanol/water (90:10 by volume), 
in the presence of 1 mmol/L of the radical scavenger HTMP, 
followed by solid-phase xtraction on C18 (Chromabond col- 
umn from Macherey Nagel, Dtiren, Germany) and further 
reverse phase high-performance liquid chromatography on a 
5-/.tm Novapak Ci8 column (Millipore, Milford, MA) as de- 
scribed. 15 Briefly, the column (0.4 × 15 cm) was isocratically 
eluted at 1 mL/min with 33.6:5.4:60:1 acetonitrile/methanol/ 
water/acetic acid (vol/vol), adjusted to pH 5.6 with triethyl- 
amine, and the absorbance at 280 nm was continuously re- 
corded. For analysis of LTs, 3-mL fractions eluting at the 
retention times of standard LTC4 and LTD4 were collected, 
evaporated under nitrogen, further resuspended in 50 mmol/ 
L Tris buffer (pH 7.5), mixed, and quantitated by a commercial 
radioimmunoassay kit (Amersham, Little Chalfont, England). 
Cross-reactivities of this kit for LTC4 and LTD4 were identical. 
Analysis of 5-Lipoxygenase Messenger 
RNA 
At the end of each stimulation experiment, a piece of 
liver was immediately frozen in liquid nitrogen and stored at 
-80°C until use for the isolation of total RNA by a guanidi- 
nium-thiocyanate/phenol/chloroform method.16 The analysis of 
5-1ipoxygenase messenger RNA (mRNA) was conducted 
through a procedure based on the reverse-transcription poly- 
merase chain reaction (RT-PCR), essentially as described, iv
Total RNA (1 gg) was reverse transcribed in a volume of 20 
[.tL. One half of the complementary DNA (cDNA) pool was 
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used for PCR amplification of a 5-1ipoxygenase cDNA frag- 
ment (595 base pairs long, located between ucleotides 1500 
and 2094 in the reported rat 5-1ipoxygenase s quence 18) using 
the primers 5' ~ 3':d(ATCGTGATGATGGACTGCTCG) 
and d(TGGAATCTGTCTGGTGACAGG). A 314-base pairs 
long fragment of rat [~-actin cDNA was amplified as an internal 
control for each sample, using 6 btL of the cDNA pool and 
the primers d(TCTACAATGAGCTGCGTGTG) and d(GGT- 
GAGGATCTTCATGAGGT), with the underlined nucleotide 
being different in the rat sequence. This ~-actin cDNA frag- 
ment corresponds to nucleotides encoding aminoacids between 
Phe-90 and Thr-194 in the reported rat [}-actin sequence. 19To 
avoid interference of the plateau effect, 5-1ipoxygenase cDNA 
fragment was amplified by 37 cycles with the step program 
94°C, 60°C, and 72°C (1 minute each except 5 minutes for a 
final extension at 72°C), and ~-actin was amplified by 22 cycles 
with the step program 94°C, 55°C, and 72°C (1 minute each 
except 5 minutes for the final extension). Blank reactions with 
no RNA were conducted in all experiments as well. For com- 
parative quantitation, labeled PCR products were obtained by 
amplification of corresponding DNA fragments in the presence 
of [32pJdeoxycytidine triphosphate. This step and the further 
processing was as described elsewhere. I~Values (in cpm) for 
5-1ipoxygenase mRNA were normalized to those for [~-actin 
mRNA, being the results given as ratios between them (5- 
lipoxygenase cpm/[3-actin cpm). The use of ~-actin mRNA as 
an internal standard has been controverted because it may vary 
in some circumstances. 2° However, this was not the case in 
our study. Thus, no differences between groups in [~-actin 
mRNA cpm values were observed in determinations performed 
simultaneously and with the same batch of labeled deoxycyti- 
dine triphosphate. 
Validation experiments ofPCR assays using known amounts 
of total RNA (0.25, 0.5, 1, and 2 btg) were performed. Resul- 
tant cpm values corresponding to either 5-1ipoxygenase or ~- 
actin mRNA had linearity with respect o input of total RNA 
within the used range. The identity of the PCR products from 
5-1ipoxygenase cDNA amplification was ascertained both by 
size and by the restriction patterns after treatment with endo- 
nucleases. PstI and PvuII yielded the predicted restriction frag- 
ments, whereas EcoRI did not digest the amplified PCR prod- 
uct (no restriction site for EcoRI was expected to be present 
in the PCR fragment). 
Measurement of [Ca2÷]~ in Hepatocytes 
Intraceilular concentration of free calcium was mea- 
sured in isolated rat hepatocytes by fluorescent labeling and 
image analysis. 2~ Hepatocytes were isolated from livers of fed 
male Wistar rats weighing 240-290 g as previously de- 
scribed. 22 Mean viability by trypan blue exclusion was ~88%. 
Cells were resuspended in Leibovitz L-15 medium containing 
50 U/mL penicillin, 50 ~g/mL streptomycin, and 10% fetal 
calf serum, plated onto laminin-treated glass coverslips (22 
mm diameter), and incubated at 37°C for 2 hours. 
Hepatocytes attached to coverslips were then loaded with 
the dye by incubating (30 minutes) with Fura-2/AM (final 
concentration, 4 -5  btmol/L) in L-15 medium enriched with 
fetal calf serum. After incubation, coverslips were transferred 
to a perfusion chamber placed into a Nikon Diaphot inverted 
microscope (Tokyo, Japan) and continuously superfused with 
Krebs-Ringer bicarbonate buffer (37°C and gassed with 95% 
02/5% CO2) , at a flow rate of 3 mE/rain. 23 
Excitation of the cells was performed with a xenon lamp 
light filtered alternatively at 340 and 380 nm by means, of a 
computer-controlled rotating filter wheel. 24 ]Neutral density 
filters reduced the excitation intensity to 0.t%. 25 Fluorescence 
was measured in fields of 15-20 cells selected to exclude 
damaged cells showing blebs or cytosolic granulations. Emis- 
sion signals were collected with a video camera (Photonic Sci- 
ences, Robertsbridge, England), and the 340/380 nm fluores- 
cence ratio was converted to calcium concentrations using a 
calibration curve prepared with the calcium ionophore iono- 
mycin. The collection of the images and all of the calculations 
were performed with an Applied Imaging MagiCal image sys- 
tem (Sunderland, England). 
Statistical Analyses 
Mann-Whitney, Wilcoxon, and Kruskal-Wallis non- 
parametric statistical tests were used to make comparisons 
between experimental groups. 26 Values are expressed as the 
mean _+ SEM. 
Results  
Effects of LTC4 on Bile Flow, Bile Salt 
Excretion, and Liver Metabolism 
LTC4, administered as a bolus of 0.25 fmol, was 
found to increase the excretion of bile salts (+22.2% 
with respect o the basal values; P < 0.05) and the bile 
flow (+11.1% with respect to the basal values; P < 
0.05) (Figure 1). These increases were also significant 
when compared with a control group with only saline 
vehicle stimulation (both P < 0.05). In contrast, ahigher 
dose of LTC4 (0.25 × 106 fmol) had a cholestatic effect, 
reducing both biliary bile salt excretion ( -25 .9% with 
respect o basal values; P < 0.01), and bile flow ( -35 .9% 
with respect o basal values; P < 0.01) (Figure 1). This 
high dose of LTC4 also induced an increase in the rate 
of glucose release to the effluent (data not shown) and 
in the lactate/pyruvate ratio as compared with a control 
with injection of vehicle alone (P < 0.05 for both) (Fig- 
ure 1). The high close of LTC4 did not modify either 
perfusion flow (4.84 + 0.04 mL" min -1"g  liver -1 vs. 
4.79 + 0.07 mL" min - l "g  liver -t  in the basal period; 
NS) or portal pressure (7.75 + 0.26 mm Hg vs. 7.63 -+ 
0.27 mm Hg in the basal period; NS). 
The specificity of the observed effects of LTC4 could be 
assessed by injecting LTC4 together with LT antagonists 
(either FPL 55712 or REV 5901; 6.25 X 106 fmol each). 
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Figure 1. Effect of bolus administrations of two different doses of 
LTC4 on bile salt excretion, bile flow, and lactate/pyruvate ratio in 
comparison with the control group and its antagonism by FPL 55712. 
Every pair of bars represents the mean value of 3 -6  independent 
experiments of isolated and perfused rat liver either in the respective 
basal period (E~) or after the administration of saline vehicle ([]) 
(control group), 0.25 fmol of LTC4 ( l )  (group A), 0.25 x 106 fmol of 
LTC4 ( l )  (group B), 0.25 fmol of LTC4 plus 6.25 x 106 fmol of FPL 
55712 (D) (group C), or 0.25 x 106 fmol of LTC4 plus 6,25 × 106 
fmol of FPL 55712 ([]) (group D), The data represent the mean _+ 
SEM. *P < 0.05 vs. the values in the respective basal period. 
The simultaneous administration of FPL 55712 and 
0.25 × 106 fmol of LTC4 prevented the reduction of 
both bile salt excretion and bile flow and the increase in 
the lactate/pyruvate ratio observed with 0.25 X 10 6 fmol 
of LTC4 alone (Figure 1). Also, the increase in the biliary 
excretion of bile salts and bile flow observed after in- 
jecting 0.25 fmol of LTC4 alone was prevented by the 
simultaneous administration of FPL 55712 (Figure 1). 
FPL 55712 alone induced a slight reduction in both bile 
flow ( -10.5%;  n = 3; NS) and bile salt excretion 
( -6 .1%;  NS). A similar result was obtained with the 
other LT antagonist (REV 5901) alone: -13 .6% for bile 
flow and -4 .7% for bile salt excretion (n = 3; both 
NS). REV 5901 also blocked the LT effects on these 
parameters in the same way as FPL 55712. Thus, a low 
dosis of LTC4 associated with REV 5901 resulted only 
in minor and nonsignificant decreases of both bile flow 
( -11.8%; n = 3), and bile salt excretion ( -3.4%),  simi- 
lar to those with REV 5901 alone. Also, no significant 
changes were observed when a high dosis of LTC4 was 
administered together with REV 5901 ( -14 .6% for bile 
flow and -11 .9% for bile salt excretion; n = 3). 
Effects of Taurocholate on Bile Secretion 
and CysteinyI-Containing LT Biosynthesis 
Figure 2 shows the effect of bolus injections with 
taurocholate (3 and 12 [.tmol) on both bile flow and 
biliary excretion of bile salts. As expected, taurocholate 
caused a significant increase of these parameters in a 
dose-dependent manner. When the biliary excretion of 
cysteinyl-containing LTs was measured before and after 
the administration of taurocholate, it was found that this 
bile salt also caused a dose-dependent increase in the 
amount of cysteinyl-containing LTs in the bile (Figure 
2). To assess whether this effect was because of hepatic 
biosynthesis of LTs or merely because of increased excre- 
tion of LTs previously produced and maintained in the 
liver, we performed a series of experiments using livers 
loaded with [3H]LTC4 before the stimulation with tauro- 
cholate. The recovery of radioactivity in bile and the 
biliary excretion of cysteinyl-containing LTs were 
measured simultaneously. Bolus injection of 3 gmol of 
taurocholate in [~H]LTC4 preloaded livers induced the 
expected increase in the biliary excretion of cysteinyl- 
containing LTs (from 3.17 -+- 0.41 to 9.32 + 1.43 
pg" min -1" g liver-*; P < 0.05) (Figure 3). This increase 
was similar to that observed after injecting taurocholate 
to non-preloaded livers (from 2.26 + 0.40 to 9.08 + 
2.12 pg" min -1 "g liver-i; P < 0.05) (Figure 2). How- 
ever, taurocholate injection did not modify the rate of 
the biliary excretion of labeled LTC4 from the preloaded 
livers (Figure 3), indicating that the increased biliary 
excretion of LTs on taurocholate administration was 
mainly due to a de novo production of these compounds 
in the liver. 
The effect of taurocholate was also studied in a contin- 
uous infusion model because it may represent a more 
physiological situation than the bolus injection. Bile flow 
and biliary excretion of bile salts were higher in livers 
perfused with taurocholate at a rate of 120 ~tmol/h than 
in control livers in which taurocholate was infused at a 
rate of 15 ~mol/h (2.08 + 0.10 vs. 1.46 -+- 0.05 
~tL" min - l 'g  liver -1 for the bile flow, respectively, and 
123.3 --- 8.5 vs. 24.7 4- 2.4 nmol" min-~'g  liver -1 for 
the excretion of bile salts, respectively; for both P < 
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0.001) (Figure 4). Similarly, the biliary excretion of cys- 
teinyl-containing LTs was significantly higher in livers 
perfused with 120 ~tmol/h oftaurocholate han in control 
livers (18.8 + 3.6 vs. 3.70 + 1.52 pg" min -I • g liver -1, 
respectively; P < 0.05) (Figure 4). 
Effect of Taurocholate on the Expression 
of 5-Lipoxygenase Gene 
To further explore the stimulating effect of tauro- 
cholate on LT biosynthesis, we studied the expression of 
5-1ipoxygenase g ne in livers challenged by either bolus 
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Figure 2. Effect of bolus administration of taurocholate on bile salt 
excretion, bile flow, and cysteinyl-containing LT excretion. [], values 
in the basal period; B, values after administration of either 3 or 12 
pmol of taurocholate. The data represent the mean _+ SEM (n = 6 
each). *P < 0.05 and **P  < 0.001 vs. the values of their respective 
basal period. 
injection or continuous infusion. As shown in Figure 
5, administration of a bolus of taurocholate nhanced 
significantly, and in a dose-dependent manner, the levels 
of 5-1ipoxygenase mRNA (represented as5-1ipoxygenase 
cpm/~-actin cpm ratio). Also, the infusion of taurocho- 
late at a high rate (120 btmol/h) caused an increase in 
the levels of 3-1ipoxygenase mRNA as compared with 
controls (where taurocholate was infused at a rate of 15 
~mol/h) (Figure 5). 
Effect of Taurocholate on [Ca2+]i in 
Isolated Rat Hepatocytes 
To test the possibility that the calcium metabo- 
lism might be involved in the stimulation of LT biosyn- 
thesis by taurocholate, isolated rat hepatocytes were ana- 
lyzed for variations of [Ca2+~. Basal levels of ~Ca2+]i were 
174.6 _+ 4.5 nmol/L (n = 60). The (z-adrenergic agonist 
t-phenylephrine (1 btmol/L) was shown to induce, as ex- 
pected, a significant increase in these levels (+456.1 + 
24.7 nmol/L; n = 16; P < 0.001). However, when tauro- 
cholate was continuously superfused (at concentrations 
of 25 and 50 btmol/L), only a minimal increase in [Ca2+~i 
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Figure 3. Analysis of the biliary excretion of cysteinyl-containing LTs 
from livers preloaded witl~ [3H]LTC4 on bolus injections with 3 pmol 
of taurocholate. 0, values of biliary cysteinyl-containing LTs measured 
by high-performance liquid chromatography radioimmunoassay; ©, 
dpm values corresponding to the biliary excretion of the [3H]LTC4 
previously added (0 minutes) to the liver. Arrows indicate the injec- 
tions of taurocholate. The data represent he mean ± SEM (n = 4). 
*P < 0.05 vs. the basal value. 
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was observed (+34.8 --- 11.1 and +26.9 + 3.6 nmol/ 
L, respectively; NS), which suggests that intracellular 
changes of calcium are not basically responsible for the 
stimulation of LT biosynthesis in the liver induced by 
taurocholate. 
Discuss ion 
Using the isolated and perfused rat liver model, 
we have studied the effects of LTC4 on bile flow and bile 
salt excretion as well as the possible ffect of taurocholate 
on the hepatic production of cysteinyl-containing LTs. 
A bolus with 0.25 fmol of LTC4 (which presumably 
reached aconcentration f 1 fmol/L in the perfusion fluid) 
induced asignificant increase in both bile flow and biliary 
excretion of bile salts, although, at a much higher dose 
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(0.25 × 106 fmol), LTC4 was found to reduce these 
parameters (Figure 1). The apparent choleretic effect ob- 
tained with the low dose of LTC4 would be in line with 
our previous data showing that 5-1ipoxygenase inhibitors 
reduce the efflux of bile salts from isolated rat hepato- 
cytes. 1* Other investigators have found that concentra- 
tions of LTC4 within our range may exert some biological 
effects in several cell systems, such as stimulation of 
luteinizing hormone releasing hormone secretion from 
hypothalamic tissue, 2v increase of the contractile activity 
of the heart, 28 and stimulation of mitogenesis n human 
airway epithelial cells. 29 These effects occurred in a nar- 
row range of LTC4 concentrations (0.1-10 fmol/L), dis- 
appearing at higher concentrations. 27-29 Our present data 
in the perfused liver agree with this phenomenon. Thus, 
increasing the concentration of the injected LTC4 turned 
a seemingly physiological choleretic effect into a chole- 
static one, the latter also being in accordance with previ- 
ous observations by Krell and Dietze 1° that LTC4 may 
induce cholestasis. The pathogenetic role of high concen- 
trations of cysteinyl-containing LTs in the liver has also 
been shown in a variety of experimental models, includ- 
ing fulminant hepatitis induced by D-galactosamine/en- 
dotoxin, 9'3°'31 carbon tetrachloride-induced liver injury, 32 
and frog virus 3-induced liver injury. 33 In our study, 
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Figure 4. Effect of continuous infusion of taurocholate on bile salt 
excretion, bile flow, and cysteinyl-containing LT excretion. II, values 
in livers infused with taurocholate at a rate of 120 ~mol/h; [], values 
in livers with taurocholate at a rate of 15 pmol/h. The data represent 
the mean _+ SEM of four separated stimulation experiments in each 
group. *P < 0.05 and **P  < 0.001 between groups. 
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Figure 5. Effect of taurocholate on the levels of 5-1ipoxygenase mRNA 
in liver tissue. Taurocholate was administered to isolated livers either 
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Materials and Methods). Values of cpm corresponding to 5-1ipoxygen- 
ase mRNA were normalized to those obtained for B-actin mRNA. The 
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tion of taurocholate; II, livers stimulated with a continuous infusion 
of taurocholate at a high rate (120 pmol/h). 
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all of the parameters of liver metabolism investigated 
were in the normal range throughout the experiments 
using the choleretic dose of LTC4, whereas a higher dose 
of LTC4 (0.25 X 106 fmol) was found to enhance both the 
lactate/pyruvate ratio (Figure 1) and the hepatic release of 
glucose. This increase in glucose release in response to 
LTC4 has been already reported by others. 34'~5 
The effects of LTC4 on bile salt excretion seem specific 
because they were reversed by LT antagonists. FPL 5 5 712 
prevented both the choleretic and the cholestatic effect 
shown by low and high LTC4 doses, respectively. Also, 
FPL 55712 was able to block the increased release of 
glucose to the effluent and the abnormally high lactate/ 
pyruvate ratio induced by high doses of LTC4 (Figure 
1). Similar effects on bile flow and bile salt excretion 
were obtained when LT administrations were associated 
with REV 5901 (see Results). 
Our data do not permit any conclusion about the 
mechanisms by which LTC4, at a relatively high concen- 
tration, decreases the biliary excretion of bile salts. Ac- 
cording to Iwai and Jungerman, 34it is unlikely that the 
hemodynamic actions of LTC4 are responsible for this 
effect in the isolated and perfused rat liver because there 
was no correlation with changes in either the portal pres- 
sure or the perfusion flow (see Results). It also seems 
unlikely that high concentrations of LTC4 could interfere 
with the sinusoidal uptake of bile salts because in other 
reports it has been shown that concentrations of LTC4 
higher than 1 nmol/L scarcely could influence the uptake 
of taurocholate from perfusare in the isolated rat liver. 35 
A competition between bile salts and LTC4 for their 
excretion to the canaliculi is unlikely as well because the 
excretion of taurocholate is mediated by a 110-kilodalton 
glycoprotein, 36-38 whereas cysteinyl-containing LTs seem 
to use a different export carrier. 37'38 It is possible that 
the cholestatic effect of LTC4 be mediated by interference 
with the hepatocytic transport of bile salts. In this con- 
text, it may be noted that some cytosolic glutathione 
transferases, which possess high-binding affinity for 
LTC4, are involved in the intrahepatocytic ransport of 
bile salts. 39 Thus, high amounts of exogenous LTC4 
reaching the liver could interfere with the binding of 
bile salts to GSH transferases, impairing their canalicular 
excretion. In addition, as suggested by the elevation in 
the lactate/pyruvate ratio, high concentrations of LTC4 
might reduce the availability of energy, which is essential 
for bile salt secretion. 
In this study, we also found that taurocholate may 
influence the production of cysteinyl-containing LTs in 
the liver. Bolus injections of taurocholate were followed 
by a dose-dependent i crease in the biliary excretion of 
both bile salts and cysteinyl-containing LTs (Figure 2). 
Continuous infusion of taurocholate had a similar effect 
on these parameters (Figure 4). Experiments in which 
livers were preloaded with labeled LTC4 show that tauro- 
cholate stimulates the excretion of LTs by enhancing 
their hepatic biosynthesis rather than through a washout 
effect of preformed cysteinyl-containing LTs maintained 
in the liver (Figure 3). Our finding of a taurocholate- 
stimulated 5-1ipoxygenase mRNA expression i  the liver 
(Figure 5) suggests that bile salts may modulate the 
liver biosynthesis of LTs by influencing, either directly 
or indirectly, the 5-1ipoxygenase g ne expression i  hepa- 
tocytes or, most probably, in nonhepatocyre c lls (e.g., 
mast cells and Kupffer cells, see below). 
It is known that the liver is a major organ for the 
disposal of cysteinyl-containing LTs of systemic origin, 4° 
but, according to our data, the liver also seems to be a 
source of cysteinyl-containing LT production. This pro- 
duction has been shown to take place in the liver only 
after immunopathologic stimuli. 4.-43 Interestingly, our 
results indicate that also physiological stimuli, such as 
bile salts, may enhance the liver production of cysteinyl- 
containing LTs. 
The mechanism by which taurocholate stimulates the 
production of LTs by the liver was not fully analyzed 
here. It has been shown that the synthesis of cysteinyl- 
containing LTs requires the membrane translocation of 
5-1ipoxygenase, and its specific binding to a membrane 
protein termed 5-1ipoxygenase-activating protein, both 
activation steps being dependent on [Ca2+] i .44,45 On the 
other hand, it has been reported that bile salts, mainly 
in the form of taurine conjugates, may act as calcium 
ionophores. 4~ However, when we studied the effect of 
taurocholare on [Ca2÷]  i in isolated rat hepatocytes, only 
a very small increase in its levels was observed, as pre- 
viously shown by others. 23 Apparently, this increase is 
not enough to account for the membrane translocation 
of 5-1ipoxygenase and synthesis of LTs. 47 Therefore, it 
is unlikely that intrahepatocytic calcium movements be 
involved in the coupling between taurocholate ransport 
and cysteinyl-containing LT biosynthesis. 
Regarding the cellular origin of LT formation, it has 
been reported that during anaphylaxis, the resident mast 
ceils are the main intrahepatic cells initiating LT biosyn- 
thesis. 43 Similarly, the Kupffer cells are known to possess 
the complete nzymatic set for the synthesis of cysteinyl- 
containing LTs, being able to produce these compounds 
when properly stimulated. 4sAlso, hepatocytes have been 
described to synthesize cysteinyl-containing LTs from 
LTA4 produced by Kupffer cells, 49 as well as from 5- 
HPETE in the presence of glutathione9 Therefore, there 
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is room for speculations about intercellular cooperation 
between diverse cell types uch as Kupffer ceils and hepa- 
tocytes, leading to transcellular metabolism ofLT precur- 
sors, as reported in several cell systems in vitro. 51-56 
In conclusion, our results how that LTC4 at low dose 
(0.25 fmol) exerts a choleretic effect, increasing the bili- 
ary secretion of bile salts. LTC4, however, induces chole- 
stasis when administered at a relatively high dose 
(0.25 × 106 fmol) (it should be emphasized that the two 
LTC4 concentrations differ in six orders of magnitude). 
This suggests a biphasic effect of the cysteinyl-containing 
LTs on the liver function, as already pointed out by 
Iwai and Jungermann in relation to the carbohydrate 
metabolism. 57 On the other hand, this study also shows 
that taurocholate stimulates the hepatic synthesis of cys- 
teinyl-containing LTs. Accordingly, it is suggested the 
existence of a positive feedback mechanism by which bile 
salts would stimulate the synthesis of cysteinyl-con- 
taining LTs, and these compounds, in turn, would pro- 
mote bile salt secretion. These observed interrelation- 
ships between bile salts and cysteinyl-containing LTs in 
the liver might be of physiological significance for the 
formation of bile. 
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